Press releases
- Press releases
- Browse
Press releases
Genesis 2010, Westminster, Thursday 9 December is on track to attract a larger than ever attendance to debate new medicines and healthcare products research. More
ReGen Therapeutics Plc ('ReGen' or 'the Company') is developing an important new use for zolpidem, a long-established and safe treatment for insomnia. More
SAN DIEGO, CA, November 22, 2010 – Jaleva Pharmaceuticals LLC announces encouraging pre-clinical results for ‘NicoFix’, Jaleva’s proprietary Nicotine Replacement Therapy product currently under development.
BioTox Sciences has completed a pre-c More
BioTox Sciences has completed a pre-c More
Hamburg, December 10th, 2010
Effective September 28th, 2010, Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina.
Amarin h More
Effective September 28th, 2010, Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina.
Amarin h More
FDA has approved Cambia™, Potassium Diclofenac Powder for Oral Solution for the treatment of acute migraine attacks with or without aura, originally developed by APR Applied Pharma Research SA (APR) using the patented Dynamic Buffering Technology (DBT). More
The International Contract Service Event (“ICSE”), taking place in Madrid from 9th until 11th October 2012, is co-located with the “CPhI Worldwide” – the biggest international fair for the pharmaceutical industry. More
Merz Pharma KGaA, specializing in the treatment of diseases of the central nervous system and of esthetic dermatology, has received approval for the first-ever pure botulinum toxin type A (BoNT/A). More
APR Applied Pharma Research s.a. opens US office in Charlotte, North Carolina More
Endo announced today that it has entered into an agreement with ProEthic to commercialize the Ketoprofen Patch developed by APR More
Cambridge, 4 November 2010 - One Nucleus, the not-for-profit membership company for international life science and healthcare companies, is to launch a series of high level conferences focused on specific technology areas, replacing its annual BioPartneri More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jun 2006 - 1068 pages - $2,495
Oct 2010 - 53 pages - $1,000
Sep 2011 - 97 pages - $3,500
Feb 2011 - 75 pages - $1,000
Jan 2010 - $75
Nov 2011 - 61 pages - $3,800
Jan 2010 - $75
Jan 2010 - $75
Apr 2008 - 250 pages - $3,995
Jan 2010 - $75
Your selection
- Therapeutic target
- Central Nervous System del
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- Age-related disorders (other)
- Amyotrophic lateral sclerosis
- CNS (other)
- Neurodegenerative disorders
- Neurological
- Pain
- Psychiatric
- Subarachnoid hemorrhage
- Traumatic brain injury
- Year
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us